Alesco Advisors’s Novavax NVAX Stock Holding History

Alesco Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-552	Closed	-$14K	–	115
2016 Q4	$14K	Sell	552 -50	-8%	-$1.46K	﹤0.01%	109
2016 Q3	$25K	Sell	602 -150	-20%	-$19.4K	﹤0.01%	111
2016 Q2	$109K	Hold	752	–	–	0.01%	105
2016 Q1	$78K	Hold	752	–	–	0.01%	105
2015 Q4	$126K	Buy	+752	New	+$116K	0.01%	107

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alesco Advisors's NVAX Position: Q1 2017 in Review

Alesco Advisors sold out of Novavax (NVAX) in Q1 2017, closing a stake of 552 shares — an estimated $14K sold.

Alesco Advisors first reported a position in NVAX in Q4 2015 and held it in 5 quarters. The position peaked at $126K in Q4 2015. 129 funds tracked by Wall St. Rank hold NVAX as of Q1 2017.

Alesco Advisors reported no remaining Novavax position as of Q1 2017 after selling out during the quarter.
Alesco Advisors sold 552 Novavax shares in Q1 2017, an estimated $14K.
Alesco Advisors first reported a position in Novavax in Q4 2015 and held it in 5 quarters.
Alesco Advisors's Novavax position peaked at $126K in Q4 2015.
129 funds tracked by Wall St. Rank held Novavax as of Q1 2017.

Based on Alesco Advisors's 13F filing for Q1 2017, filed 15 May 2017.